Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S. Sabatine, Terje R. Pedersen, Robert P. Giugliano et al.|New England Journal of Medicine|2017Cited by 6k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsMarc S. Sabatine, Evan A. Stein, Robert P. Giugliano et al.|New England Journal of Medicine|2015Cited by 1.5k
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsStephen J. Nicholls, Steven E. Nissen, John J.P. Kastelein et al.|JAMA|2016Cited by 1.1k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Evan A. Stein et al.|The Lancet|2014Cited by 750
A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaDirk Blom, Evan A. Stein, Tomas Hala et al.|New England Journal of Medicine|2014Cited by 712